AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03788031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acuity training
Description: The intervention will be a vision therapy. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to identify the location of the stimulus.
Study NCT03788031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acuity training
Description: The intervention will be a vision therapy. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to identify the location of the stimulus.
Study NCT02855190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-citrate and 18F-FDG PET scans
Description: 68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
Study NCT03788031 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Occlusion therapy
Description: Participants will be required to patch the good eye for 20 days, 1 hour per day.
Study NCT04371484 — intervention group
Intervention type: OTHER
Intervention: ICD-10
Description: A collection of ICD-10 codes used within the PMSI that relate to physical abuse.
Study NCT05072691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CSF immunoglobulin (Ig) free light chains (FLC) dosage
Description: CSF immunoglobulin (Ig) free light chains (FLC) dosage in the peripheral blood and cerebrospinal fluid.
Study NCT02087046 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ANS Totally Implantable Deep Brain Stimulation System
Description: ANS Totally Implantable Deep Brain Stimulation System will be implanted in the VIM nucleus of the thalamus
Study NCT00815295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
Study NCT02144064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
Study NCT00917579 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: A single 10 mg dose of marketed 10 mg atorvastatin tablets
Study NCT00917579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A single 10 mg dose of new formulation of 10 mg atorvastatin
Study NCT02404597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICOM (non-invasive cardiac output monitor)
Description: The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure \<100 or mean arterial pressure \<65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined.
Study NCT00063128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin
Description: * Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.~* Inject into abdomen only.
Study NCT02692326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyclic parenteral nutrition
Description: Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies \< 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
Study NCT00754338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Opti-Free® RepleniSH® with Supraclens®
Description: Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
Study NCT00063128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin inhalation powder (HIIP)
Description: * Administer HIIP within 15 minutes before meals.~* Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~* Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin
Study NCT04153253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection [Eylea]
Description: Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection.
Study NCT04153253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Was done under local peribulbar anesthesia. After sterilization and toweling, wash with diluted betadine 5% was done. Insertion of three 23 valved cannulas beginning with the lower temporal one for infusion, clearance of anterior vitreous was done followed by core vitrectomy, peripheral vitrectomy , removal of posterior hyaloid aided by triamcinolone staining , trimming and removal of any vascular epicenters followed by vitreous base shaving with 360 scleral indentation, endolaser treatment was done for all eyes followed by fluid air exchange, 20% SF6 was used only if there is active significant bleeding during surgery or if there is intraoperative retinal tears, removal of cannulas was done at the end of surgery. All eyes received combination of topical steroid and antibiotic eye drops as postoperative treatment.
Study NCT01188707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat and Erlotinib
Description: The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.~When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.~3 patients will be treated at each dose level.
Study NCT01549288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified Atkins diet
Description: Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
Study NCT01549288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no dietetic input
Description: continuation of anti-epileptic medication without any dietetic input
Study NCT02564900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a (DP1)
Description: DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.
Study NCT02564900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a (DP2)
Description: DS-8201a is to be administered via intravenous (IV) dose. DS-8201a (DP2) was used only used for Dose Expansion Part 2e.
Study NCT02564900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a (DP)
Description: DS-8201a (DP) is to be administered via intravenous (IV) dose.
Study NCT01146093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin Sodium
Description: Pravastatin Sodium Tablets 80 mg
Study NCT01146093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin Sodium
Description: Pravastatin Sodium Tablets 80 mg
Study NCT03003494 — intervention group
Intervention type: DRUG
Intervention: Spiolto® Respimat®
Description: observations taken in a period of approximately 6 weeks
Study NCT00185263 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AdF5FGF-4 vs. Placebo
Description: Intracoronary infusion
Study NCT00754338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcon Opti-Free® RepleniSH®
Description: Marketed Multipurpose Disinfecting Care System
Study NCT01854788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autogenic drainage
Description: It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
Study NCT01854788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow expiration with glottis opened in lateral posture
Description: It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
Study NCT01854788 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temporary-positive expiratory pressure
Description: The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
Study NCT01299038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: Taken orally once a day for 4 weeks
Study NCT00754338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B&L ReNu MultiPlus™
Description: Marketed Multipurpose Disinfecting Care Systems
Study NCT00185263 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: AdF5FGF-4 vs. Placebo
Description: Intracoronary infusion
Study NCT02551471 — intervention group
Intervention type: OTHER
Intervention: Semi-structured exploratory interviews and focus group with MDT health professional attendees
Description: Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
Study NCT00005807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-247550
Description: anticancer agent for the treatment of patients with malignant tumors.
Study NCT02752061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potlako intervention
Description: Multicomponent intervention including:~* provider training on early detection and diagnostic approaches to cancer~* patient education on importance of obtaining timely cancer diagnosis~* provision of a patient navigator to facilitate diagnosis and entry into care~* provision of transportation support to vulnerable patients
Study NCT01748500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study NCT02889939 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: UC + ETT
Description: UC: A 3-week UC period, where the participants were not offered any new rehabilitation activities but were allowed to continue their regular treatment for a maximum of 3 hours per week.~ETT: The rehabilitation facilities were located in a climate that allowed and encouraged both indoor and outdoor activities. The ETT was individually tailored. Participants exercised in the same room/place as the other participants in groups of 4-9. Physical exercise was scheduled 3.5-6 hours per day, 5½ days per week for 3 weeks. The training was characterized by repetitive mass practice of gradually increasing difficulty and noncompensatory strategies, such as enforcing use of the affected side.~Beyond scheduled activities, participants were encouraged to physically engage themselves in a challenging outdoor environment.
Study NCT03829254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUC-7738
Description: NUC-7738
Study NCT03829254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab
Study NCT03382834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg orally
Study NCT03382834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 400 mg orally
Study NCT03382834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: 400 mg orally
Study NCT03382834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral drugs
Description: Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
Study NCT03382834 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral drugs
Description: Participants will receive antiretroviral drugs provided by their own doctors. Antiretroviral drugs will not be provided by the study.
Study NCT03475862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-821 capsule Manipulated
Description: PTI-821 (oxycodone) 40 mg extended release capsule
Study NCT03475862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-821 Non-manipulated
Description: PTI-821 (oxycodone) 40 mg capsule extended release capsule
Study NCT03475862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyContin
Description: Crushed OxyContin (oxycodone) extended-release 40 mg tablet
Study NCT03475862 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebos for PTI-821 and oxycodone IR
Study NCT03475862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Crushed oxycodone 40 mg immediate release tablet
Study NCT01320007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preset increase in frusemide dose
Description: All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week.
Study NCT01320007 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
Study NCT03546517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
Study NCT03546517 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needling
Description: Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
Study NCT03647306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Total Caloric Intake
Description: Provide subjects a regimented amount of calories at each meal.
Study NCT03647306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Total Caloric Intake
Description: Provide subjects a regimented amount of calories at each meal.
Study NCT03647306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extended Overnight Fast
Description: Provide subjects a regimented amount of calories at each meal.
Study NCT01851148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
Study NCT01851148 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham treatment
Description: Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence
Study NCT03199170 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intrathecal morphine
Description: 0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
Study NCT03199170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral Quadratus Lumborum Block
Description: 0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
Study NCT03199170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine with bilateral Quadratus Lumborum Block
Description: 0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
Study NCT02945462 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cells
Description: Patients will be injected with autologous mesenchymal stem cells, intracavernously
Study NCT05118321 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Custom-made upper limb exosuit and hand exoskeleton
Description: Participants go through 3 90-min sessions in a clinic setting and perform a series of functional tasks adapted from motor activity log and bilateral upper limb tasks with and without the device.
Study NCT04611659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing and Educational Training (MIET)
Description: Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
Study NCT04611659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Educational Training (MIET)
Description: Women in the intervention arm will receive a motivational interviewing intervention coupled with education on contraception and the potential for neonatal abstinence syndrome.
Study NCT03691207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL101
Description: AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenously
Study NCT04520997 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Up to 2 milliliters (ml) of Restylane Defyne per treatment site (chin and surrounding area) with maximum of total 4 ml at baseline, up to 2 ml of Restylane Defyne per NLF and ML at week 3 and optional up to 2 ml of Restylane Defyne per facial half for NLF and ML in combination with a total of 2 ml in the chin and surrounding area at week 6.
Study NCT04402749 — intervention group
Intervention type: OTHER
Intervention: Nephrectomy
Description: Patients underwent nephrectomy
Study NCT03013933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT03013933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT03013933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT03013933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Given PO
Study NCT03013933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride
Description: Given PO
Study NCT00909077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets: 40 mg/day for four days
Study NCT00909077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone and Rituximab
Description: Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m\^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
Study NCT00648856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Hydrochloride Tablets 100 mg
Description: 100mg, single dose fed
Study NCT00648856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® Tablets 100 mg
Description: 100mg, single dose fed
Study NCT00929357 — intervention group
Intervention type: DRUG
Intervention: DMARDs or Biologics
Study NCT01720628 — intervention group
Intervention type: OTHER
Intervention: serum levels of angiogenin, bFGF, VEGF
Description: Behçet's patients
Study NCT01851148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptans
Description: administration of triptans drug treatment according to international guidelines